Exhibit 4.8
FORM 51-102F3
MATERIAL CHANGE REPORT
Item 1. Name and Address of Company
Neovasc Inc. (the “Company”)
13700 Mayfield Place, Suite 2135
Richmond, BC,
V6V 2E4
Item 2. Date of Material Change
May 8, 2014
Item 3. News Release
A news release announcing this material change was issued May 8, 2014 and a copy has been filed on SEDAR.
Item 4. Summary of Material Changes
On May 8, 2014, the Company announced that Vicki Bebeau joined the Company in the role of Vice President, Clinical Affairs.
Item 5. 5.1 — Full Description of Material Change
On May 8, 2014, the Company announced that Vicki Bebeau joined the Company in the role of Vice President, Clinical Affairs. The position of Vice President, Clinical Affairs is a newly created position with the Company.
Ms. Bebeau joins the Company as it begins to prepare formal clinical feasibility studies for its Tiara device for the transcatheter treatment of mitral valve disease and the design of a US-IDE study to support an application for FDA approval of the Reducer. The Company anticipates beginning the Tiara device study towards the end of the 2014 calendar year with the Reducer study expected to begin in 2015.
5.2 — Disclosure for Restructuring Transactions
Not applicable.
Item 6. Reliance on subsection 7.1(2) of National Instrument 51-102
Not applicable.
Item 7. Omitted Information
Not applicable.
Item 8. Executive Officer
For further information, please contact Chris Clark, Chief Financial Officer of the Company, at 604-270-4344.
Item 9. Date of Report
May 9, 2014.